Posted in

CNPD3

CNPD3 Seminar Series Invites Dr. Shaomeng Wang from The University of Michigan

Proteolysis targeting chimera (PROTAC) technology has recently gained a tremendous momentum for its promise to discover and develop an entirely new type of medicines by inducing targeted protein degradation. Our laboratory has employed the PROTAC technology to discover and develop small-molecule degraders to target a large number of proteins, including…